Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic Disease
Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic Disease
批准号:
9752627
负责人:
Lbachir BenMohamed
金额:
$37.5万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-08-01 至 2022-07-31
关键词:
AddressAdultAffectAfferent NeuronsAntiviral AgentsBlindnessCD8-Positive T-LymphocytesCD8B1 geneCellsCellular immunotherapyClinicalCorneaCorneal DiseasesDefense MechanismsDevelopmentDiseaseDisease modelEpitopesExperimental ModelsEyeEye diseasesFoundationsFrequenciesGenesGoalsHLA AntigensHLA-A geneHLA-DR AntigensHerpesviridae InfectionsHerpesvirus 1Herpetic KeratitisHumanImmuneImmune EvasionImmune systemImmunityImmunizationImmunologic MonitoringImmunologicsImmunotherapeutic agentImmunotherapyIn VitroIndividualIndustrializationInfectionInterventionKnowledgeLatent VirusLeadLongevityMemoryModelingNaturePathologicPhenotypePlayPreventionProteinsPublishingRecurrenceRecurrent diseaseResearch Project GrantsRoleScientistSeveritiesSeverity of illnessSideSimplexvirusStructure of trigeminal ganglionT VirusT-LymphocyteT-Lymphocyte EpitopesT-Lymphocyte SubsetsTestingTherapeuticTimeTransgenic MiceTranslational ResearchUV inducedUnited StatesVaccine TherapyVaccinesViralVirusVirus DiseasesVirus LatencyVirus SheddingVisionacute infectionadaptive immunitybaseexhaustexhaustioninnovationirradiationlatency associated transcriptlatent infectionmouse modelmultidisciplinarynovelpathogenperipheral bloodpre-clinical researchpreventprophylacticprotective efficacyreactivation from latencyresponsesmall moleculetherapeutic vaccine
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Recurrent herpetic disease, caused by an immuno-pathological response to herpes simplex virus (HSV-1), is a
major cause of infectious blindness in the United States. Although most individuals shed HSV-1 in their tears
following reactivation of latent (dormant) virus from the trigeminal ganglia (TG), they never develop recurrent
ocular herpetic disease and are asymptomatic (ASYMP). In contrast, a small number of individuals are
symptomatic (SYMP), with frequent bouts of recurrent disease. Our long-term goal is to delineate the immune
mechanisms that control recurrent herpetic disease, with an eye toward developing a long-lasting antiviral
immuno-therapy that successfully prevents or ameliorates recurrent ocular herpes. It has been established that:
(1) adaptive immunity, and particularly antiviral CD8+ T cells, protect, in vitro, from HSV-1 reactivation in latently
infected TG; and (2) the HSV-1 latency associated transcript (LAT), the only gene that is expressed during
latency, restrains the function of antiviral CD8+ T cells. However, key knowledge gaps still remain including: (1)
the mechanisms by which CD8+ T cells protect from reactivation, virus shedding in tears, and recurrent disease;
and (2) the immune evasion strategies evolved by the virus as a counter-defense against the host’s CD8+ T cells.
We recently made four discoveries that serve as the foundation for this proposal: (1) Peripheral blood-derived
HSV-specific CD8+ T cells from ASYMP individuals are mostly effector memory (TEM) cell subset, in contrast to
mostly central memory (TCM) cell subset in SYMP individuals. (2) Using our novel double transgenic mouse
model, expressing Human Leukocyte Antigens HLA-DR and HLA-A*02:01 (HLA Tg mice), multiple recurrences
of ocular herpetic disease can be induced by UV-B irradiation, closely mimicking SYMP clinical recurrent herpetic
disease. (3) TG-resident CD8+ TRM cells are associated with ASYMP herpes infection of HLA Tg mice. (4)
Exhausted (dysfunctional) CD8+ TRM cells in the cornea and TG are associated with SYMP recurrent disease.
Building on these preliminary and published findings, our central hypothesis is that interactions between
specific subsets of TG- and cornea-resident CD8+ T cells and viral factors determine the development of
recurrent herpetic disease. We propose the following Specific Aims: Aim 1: Test the hypothesis that, similar to
humans, HSV-specific CD8+ T cells from latently infected ASYMP HLA Tg mice are mostly TEM/TRM, while in
SYMP HLA Tg mice (one or more episodes of UV-B induced recurrent disease) they are mostly TCM. Aim 2: Test
the hypothesis that therapeutic vaccination with ASYMP CD8+ TEM/TRM cell epitopes, but not with SYMP CD8+
TCM epitopes, will reduce virus reactivation and lessen recurrent herpetic disease in HLA Tg mice. This
translational research project, which gathers a multidisciplinary team, addresses the current NEI Audacious
Goals Initiative: “Development of new treatments through small molecules approach to treat eye disease and to
restore sight.” Successful completion of this project will lay the foundation toward developing an effective
immunotherapeutic intervention to prevent blinding recurrent herpetic disease.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1186/s13054-018-2164-0
发表时间:
2018-10-05
期刊:
Critical care (London, England)
影响因子:
--
作者:
[Samary CS, Ramos AB, Maia LA, Rocha NN, Santos CL, Magalhães RF, Clevelario AL, Pimentel-Coelho PM, Mendez-Otero R, Cruz FF, Capelozzi VL, Ferreira TPT, Koch T, de Abreu MG, Dos Santos CC, Pelosi P, Silva PL, Rocco PRM]
通讯作者:
Rocco PRM
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes
-
批准号:10318146
-
项目类别:
-
资助金额:$61.29万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing a Multi-epitope Pan-Coronavirus Vaccine
-
批准号:10171239
-
项目类别:
-
资助金额:$74.54万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes
-
批准号:10546435
-
项目类别:
-
资助金额:$61.29万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes
-
批准号:9913971
-
项目类别:
-
资助金额:$69.75万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing a Multi-epitope Pan-Coronavirus Vaccine
-
批准号:10231272
-
项目类别:
-
资助金额:$71.8万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing a Multi-epitope Pan-Coronavirus Vaccine
-
批准号:10669702
-
项目类别:
-
资助金额:$74.22万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes
-
批准号:10083701
-
项目类别:
-
资助金额:$68.49万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing a Multi-epitope Pan-Coronavirus Vaccine
-
批准号:10454975
-
项目类别:
-
资助金额:$75.69万
-
财政年份:2020
-
负责人:Lbachir BenMohamed
-
依托单位:
Mucosal Chemokines and CD8+ T Cell Immunity to Genital Herpes
-
批准号:10223136
-
项目类别:
-
资助金额:$60.33万
-
财政年份:2019
-
负责人:Lbachir BenMohamed
-
依托单位:
Mucosal Chemokines and CD8+ T Cell Immunity to Genital Herpes
-
批准号:10450154
-
项目类别:
-
资助金额:$59.97万
-
财政年份:2019
-
负责人:Lbachir BenMohamed
-
依托单位:
Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic Disease
-
批准号:9183816
-
项目类别:
-
资助金额:$38.81万
-
财政年份:2016
-
负责人:Lbachir BenMohamed
-
依托单位:
LAT-HVEM Interactions Effect HSV-1 Latency/Reactivation
-
批准号:9084450
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2015
-
负责人:Lbachir BenMohamed
-
依托单位:
Blockade of T-cell Co-Inhibitory Pathways & Immunotherapy to Prevent Ocular Herpe
-
批准号:9121574
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2014
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:7986401
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:8523888
-
项目类别:
-
资助金额:$34.88万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:8327246
-
项目类别:
-
资助金额:$36.72万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:9112499
-
项目类别:
-
资助金额:$46.35万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:8128628
-
项目类别:
-
资助金额:$36.72万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits
-
批准号:8710229
-
项目类别:
-
资助金额:$35.99万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
Developing A Tissue-Targeted Ocular HSV Therapeutic Vaccine
-
批准号:10600045
-
项目类别:
-
资助金额:$41.0万
-
财政年份:2010
-
负责人:Lbachir BenMohamed
-
依托单位:
海外基金